Cargando…

Long COVID — metabolic risk factors and novel therapeutic management

Cardiometabolic conditions, including type 1 and type 2 diabetes mellitus, are associated with severe COVID-19 and long COVID. Interventions to target multiple risk factors, combined with use of novel glucose-lowering agents that improve metabolic function and the key processes that are impaired in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khunti, Kamlesh, Davies, Melanie J., Kosiborod, Mikhail N., Nauck, Michael A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8054121/ https://www.ncbi.nlm.nih.gov/pubmed/33875855 http://dx.doi.org/10.1038/s41574-021-00495-0

Ejemplares similares

Urgent actions and policies needed to address COVID-19 among UK ethnic minorities
por: Mathur, Rohini, et al.
Publicado: (2020)

COVID-19 and ethnicity: who will research results apply to?
por: Treweek, Shaun, et al.
Publicado: (2020)

The therapeutic validation of long COVID
por: Faust, Jeremy Samuel
Publicado: (2023)

Long covid: risk factors, outcomes, and future directions for research
por: O'Mahoney, Lauren, et al.
Publicado: (2022)

Long COVID: systemic inflammation and obesity as therapeutic targets
por: Florencio, Lidiane L, et al.
Publicado: (2022)

Charting a course for the management of long COVID
por: Beasley, Richard, et al.
Publicado: (2021)

A Review of Exenatide: Optimizing Glycemic Control and Associated Cardiovascular Risk Factors in Type 2 Diabetes
por: Htike, Zin Z., et al.
Publicado: (2012)

Are clinical outcomes from COVID-19 improving in ethnic minority groups?
por: Pan, Daniel, et al.
Publicado: (2023)

From emergency response to long-term management: the many faces of the endemic state of COVID-19
por: Contreras, Seba, et al.
Publicado: (2023)

Obesity and risk of COVID-19: analysis of UK biobank
por: Yates, Thomas, et al.
Publicado: (2020)

COVID-19 and risk management in a tissue bank
por: Paggiaro, André Oliveira, et al.
Publicado: (2020)

Global surveillance, research, and collaboration needed to improve understanding and management of long COVID
por: Ward, Helen, et al.
Publicado: (2021)

Data from network meta-analyses can inform clinical practice guidelines and decision-making in diabetes management: perspectives of the taskforce of the guideline workshop
por: Ceriello, Antonio, et al.
Publicado: (2023)

Pre-assessment and management of long COVID patients requiring elective surgery: challenges and guidance
por: Boles, Sophie, et al.
Publicado: (2023)

Managing COVID-19 importation risks in a heterogeneous world
por: Cauchemez, Simon, et al.
Publicado: (2021)

Understanding the restrictions in the prescription and use of potentially beneficial diabetes medications associated with low socio-economic status
por: Nauck, Michael A., et al.
Publicado: (2022)

The Effectiveness of Screening for Diabetes and Cardiovascular Disease Risk Factors in a Community Pharmacy Setting
por: Willis, Andrew, et al.
Publicado: (2014)

Sulfasalazine: a risk factor for severe COVID-19?
por: Konig, Maximilian F, et al.
Publicado: (2022)

COVID-19, ethnicity and cardiometabolic disease self-management in UK primary care
por: Highton, Patrick J., et al.
Publicado: (2020)

The teachings of Long COVID
por: Alwan, Nisreen A.
Publicado: (2021)

Health Perception among Female COVID-19 Patients. Comment on Fernández-de-las-Peñas et al. Female Sex Is a Risk Factor Associated with Long-Term Post-COVID Related-Symptoms but Not with COVID-19 Symptoms: The LONG-COVID-EXP-CM Multicenter Study. J. Clin. Med. 2022, 11, 413
por: Ayuso García, Blanca, et al.
Publicado: (2022)

Long COVID and kidney disease
por: Yende, Sachin, et al.
Publicado: (2021)

Long COVID: long-term health outcomes and implications for policy and research
por: Al-Aly, Ziyad, et al.
Publicado: (2022)

Long-term Benefits of Risk Factor Reduction in Takotsubo Cardiomyopathy.—A Comment on Khalighi et al. Entitled “Takotsubo Cardiomyopathy: A Long Term Follow-up Shows Benefit with Risk Factor Reduction”, J. Cardiovasc. Dev. Dis., 2015, 2, 273–281.
por: Ponamgi, Shiva P., et al.
Publicado: (2016)

Long COVID: aiming for a consensus
por: Munblit, Daniel, et al.
Publicado: (2022)

Rising diabetes diagnosis in long COVID
por: Narayan, K M Venkat, et al.
Publicado: (2022)

Prevention of long COVID: progress and challenges
por: Al-Aly, Ziyad
Publicado: (2023)

Are BCL6 and EZH2 novel therapeutic targets for systemic lupus erythematosus?
por: Ding, Shu, et al.
Publicado: (2022)

COVID-19 and hypertension: risks and management. A scientific statement on behalf of the British and Irish Hypertension Society
por: Clark, Christopher E., et al.
Publicado: (2021)

Bottom-up citizen engagement for health emergency and disaster risk management: directions since COVID-19
por: Chan, Emily Ying Yang, et al.
Publicado: (2021)

Social vulnerability as a risk factor for death due to severe paediatric COVID-19
por: Mujica, Oscar J, et al.
Publicado: (2021)

Ensuring continued progress for development of COVID-19 therapeutics in children
por: Noel, Gary J., et al.
Publicado: (2021)

ARF risk factors: Beyond a sore throat
por: Williams, Ashley N., et al.
Publicado: (2022)

Long COVID: an estrogen-associated autoimmune disease?
por: Ortona, Elena, et al.
Publicado: (2021)

Cardiometabolic syndrome — an emergent feature of Long COVID?
por: Frere, Justin J., et al.
Publicado: (2022)

Is there a role for the adrenal glands in long COVID?
por: Kanczkowski, Waldemar, et al.
Publicado: (2022)

Long COVID-19: Rethinking mental health
por: Gallegos, Miguel, et al.
Publicado: (2022)

Difficult questions about long COVID in children
por: Rytter, Maren Johanne Heilskov
Publicado: (2022)

Sleep disturbances, dyspnoea, and anxiety in long COVID
por: McGuire, W Cameron, et al.
Publicado: (2023)

Shedding light on the work burden of long COVID
por: Lemogne, Cédric, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_omrvtiqdaf23mevq593jevubnn